Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026. Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results